as of 01-16-2026 3:39pm EST
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | RADNOR |
| Market Cap: | 1.5B | IPO Year: | 2020 |
| Target Price: | $12.78 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.03 - $15.69 | Next Earning Date: | 02-25-2026 |
| Revenue: | $415,551,000 | Revenue Growth: | 11.47% |
| Revenue Growth (this year): | 10.75% | Revenue Growth (next year): | 6.32% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
CHIEF EXECUTIVE OFFICER
Avg Cost/Share
$8.30
Shares
24,096
Total Value
$199,999.99
Owned After
2,360,769.384
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Feehery William F | CERT | CHIEF EXECUTIVE OFFICER | Nov 11, 2025 | Buy | $8.30 | 24,096 | $199,999.99 | 2,360,769.384 |
See how CERT stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "CERT Certara Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.